BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 24374149)

  • 1. Antiviral strategies for hepatitis E virus.
    Debing Y; Neyts J
    Antiviral Res; 2014 Feb; 102():106-18. PubMed ID: 24374149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis E Virus Drug Development.
    Kinast V; Burkard TL; Todt D; Steinmann E
    Viruses; 2019 May; 11(6):. PubMed ID: 31141919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral therapy in chronic hepatitis E: a systematic review.
    Peters van Ton AM; Gevers TJ; Drenth JP
    J Viral Hepat; 2015 Dec; 22(12):965-73. PubMed ID: 25760481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis E: when to treat and how to treat.
    Abbas Z; Afzal R
    Antivir Ther; 2014; 19(2):125-31. PubMed ID: 24192696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapeutic targets for hepatitis C virus infection.
    Jesudian AB; de Jong YP; Jacobson IM
    Clin Gastroenterol Hepatol; 2013 Jun; 11(6):612-9.e1. PubMed ID: 23583900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis E in a patient with HIV infection.
    Dalton HR; Keane FE; Bendall R; Mathew J; Ijaz S
    Ann Intern Med; 2011 Oct; 155(7):479-80. PubMed ID: 21969351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and management strategies for chronic hepatitis E infection.
    Abravanel F; Lhomme S; Marion O; Péron JM; Kamar N; Izopet J
    Expert Rev Anti Infect Ther; 2023 Feb; 21(2):143-148. PubMed ID: 36625025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication.
    Praditya DF; Klöhn M; Brüggemann Y; Brown LE; Porco JA; Zhang W; Kinast V; Kirschning A; Vondran FWR; Todt D; Steinmann E
    Antiviral Res; 2022 Aug; 204():105359. PubMed ID: 35728703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.
    Kamar N; Rostaing L; Abravanel F; Garrouste C; Lhomme S; Esposito L; Basse G; Cointault O; Ribes D; Nogier MB; Alric L; Peron JM; Izopet J
    Gastroenterology; 2010 Nov; 139(5):1612-8. PubMed ID: 20708006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment of Chronic Hepatitis E After an Orthotopic Liver Transplant With Ribavirin Monotherapy.
    Klein F; Neuhaus R; Hofmann J; Rudolph B; Neuhaus P; Bahra M
    Exp Clin Transplant; 2015 Jun; 13(3):283-6. PubMed ID: 24779678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.
    Todt D; Moeller N; Praditya D; Kinast V; Friesland M; Engelmann M; Verhoye L; Sayed IM; Behrendt P; Dao Thi VL; Meuleman P; Steinmann E
    Antiviral Res; 2018 Sep; 157():151-158. PubMed ID: 30036559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse.
    Todt D; Meister TL; Steinmann E
    Curr Opin Virol; 2018 Oct; 32():80-87. PubMed ID: 30384328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
    Todesco E; Mazzola A; Akhavan S; Abravanel F; Poynard T; Roque-Afonso AM; Peytavin G; Marcelin AG; Calmus Y; Lecuyer L; Guillemain R; Conti F
    Antivir Ther; 2018; 23(5):463-465. PubMed ID: 29504509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis E, the neglected one.
    Blasco-Perrin H; Abravanel F; Blasco-Baque V; Péron JM
    Liver Int; 2016 Jan; 36 Suppl 1():130-4. PubMed ID: 26725910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hepatitis E virus.
    Dalton HR; Kamar N
    Curr Opin Infect Dis; 2016 Dec; 29(6):639-644. PubMed ID: 27607911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Hepatitis E Viral Infection After Liver Transplantation: A Regression of Fibrosis After Antiviral Therapy.
    Mazzola A; Tran Minh M; Charlotte F; Hdiji A; Bernard D; Wendum D; Calmus Y; Conti F
    Transplantation; 2017 Sep; 101(9):2083-2087. PubMed ID: 28376032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin.
    Lhomme S; DebRoy S; Kamar N; Abravanel F; Metsu D; Marion O; Dimeglio C; Cotler SJ; Izopet J; Dahari H
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31323954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.